^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FOXA1 expression + ER positive

    i
    Other names: FOXA1, Forkhead Box A1, Hepatocyte Nuclear Factor 3-Alpha, Forkhead Box Protein A1, Transcription Factor 3A, HNF-3-Alpha, HNF-3A, TCF-3A, HNF3A, TCF3A, Hepatocyte Nuclear Factor 3 Alpha, ESR1, Era, ESR, NR3A1, ER, ER beta
    Entrez ID:
    2099; 3169
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    1year
    Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial. (PubMed, Breast Cancer Res)
    Expression of FOXA1 is a promising predictive biomarker for tamoxifen effect in ER+/HER2- premenopausal breast cancer. In addition, each of the signatures BC proliferation, Hypoxia, Mast cells, and the GEX of AR, ESR1, and PGR had prognostic value, also after adjusting for established prognostic factors. Trial registration This trial was retrospectively registered in the ISRCTN database the 6th of December 2019, trial ID: https://clinicaltrials.gov/ct2/show/ISRCTN12474687 .
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • AR (Androgen receptor) • FOXA1 (Forkhead Box A1)
    |
    ER positive • HER-2 negative • HER-2 expression • EGFR positive • ER expression • ER-L • FOXA1 expression + ER positive
    |
    nCounter® Breast Cancer 360™ Panel
    |
    tamoxifen